Searched for
CDMO PARTNERS
India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- True North buys 25% stake in pharma co EmbioPrivate equity firm True North is investing approximately $50 million in Embio Ltd. Embio manufactures Active Pharmaceutical Ingredients fo...
- Infosys Q4 profit spikes; Flipkart mulls separate app for MinutesInfosys closed FY26 with strong numbers aided by a pickup in demand from its banking, energy and communication segments. This and more in...
- STCH bets on AI to fix trial-and-error in fabric R&D, raises $5.5 million from Omnivore, Kae CapitalSTCH is revolutionizing fabric development with AI. The company helps fashion brands design and source materials efficiently. This platform...
- Warburg-Mubadala team up, emerge as frontrunner for EncubeThe consortium is competing against EQT. Mumbai-based pharma co likely to be valued at $1.8 bn. Binding bids are scheduled for next week.
- Nandan Nilekani’s Fundamentum leads $15 million bet on materials science startup WhizzoWhizzo has raised $15 million in a round led by Nandan Nilekani’s Fundamentum, with participation from South Korea-based deeptech player LB...
- US Tariffs: Only Sun Pharma exposed to some headline risk, but with limited earnings impactUS tariffs on patented drugs begin October 1. Indian drug makers will likely see limited impact. Generic medicines are exempt from these ne...
- China’s India headache: The growing pharmaceutical industryIndian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desir...
- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- India could account for 8-10 pc of work share outsourced to CDMOs by 2033: ReportIndia could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to wor...
- Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiaryLupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development ...
- Lupin appoints Abdelaziz Toumi as CEO of newly formed armLupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech...
- JB Pharma expects India business to grow above market growth rate in FY25: CEO Nikhil ChopraJB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is d...
- Maiva Pharma raises Rs 1000 crore from Morgan Stanley Private Equity, InvAscentMorgan Stanley PE Asia and India Life Sciences Fund are investing almost equally, total stake with both funds combined will be over 60% pos...
- Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman"We want to be a diversified, end-to-end capability outsourcing partner, serving customers from development to commercial scale. Doing this...
- PE Advent completes acquisition of Suven Pharma, appoints new Board and management teamPrivate equity firm Advent International has completed its majority acquisition of Indian contract development and manufacturing organisati...
- Stelis Biopharma receives establishment inspection report from USFDAThis follows the abbreviated quality system inspection technique drug pre-approval on-site inspection specifically conducted by the US Food...
- Piramal Pharma invests Rs 102 crore in Yapan Bio for significant minority stakeBiologics capabilities can be synergistic with the company's anti-body drug conjugation capabilities; specifically, for customers who prefe...
- Encube Ethicals gets funding from Quadria Capital, others at $800 million valuationEncube Ethicals’ funding round, that saw participation of Quadria Capital and Gulf Islamic Investments, provides an exit to early backer Re...
Load More
